On Tuesday, the National Cancer Institute published its annual report on the state of the cancer research field.
In addition to the annual NIH budget and budgeted medical expenses, the report also includes information on grants awarded and how much money each agency spends on research.
Here are some of the highlights from the report:A few notable points:The report focuses on two categories of research: advanced cancer therapies and novel therapies.
A new drug that is in Phase III clinical trials is called TNF-α, and the FDA approved it in July, according to the NIH.
Treatment with the drug is available for about $40,000 per year for a total cost of about $150 million per year.
The agency also said that there is an active, clinical trial in the U.S. that is currently recruiting patients.
More than $3 billion in research dollars are going to new and emerging cancer treatments, and it is projected to double by 2025, according the report.
The NIH expects that $3.5 billion will be spent on the treatment of advanced cancer over the next decade, with about $4.5 trillion in total funding.
An estimated $8.5 million of the $9.5 to $9 billion that will be invested in the treatment centers over the decade is expected to be spent in the following five years.
The NIH also said there is a strong interest in the discovery of new drugs, but there is limited evidence to support their use.
A significant amount of research into novel treatments is already underway, but some of those projects are not progressing, the agency said.
“There is no reason to think that there will not be additional discoveries in the next five to 10 years,” the NIH said.